The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.98
Bid: 6.52
Ask: 6.98
Change: 0.13 (1.90%)
Spread: 0.46 (7.055%)
Open: 6.98
High: 6.98
Low: 6.98
Prev. Close: 6.85
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Jul 2014 11:08

RNS Number : 9756M
Synairgen plc
22 July 2014
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Synairgen plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

IP Group plc

4. Full name of shareholder(s)  (if different from 3.):iv

See section 9

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 July 2014

6. Date on which issuer notified:

21 July 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1p Shares

 

 

14,269,284

 

 

14,269,284

Below 3%

GB00B0381Z20

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

Below 3%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Direct interests:

 

IP2IPO Limited and IP2IPO Management Limited, both 100% owned subsidiaries of IP Group plc.

 

Indirect interests:

 

IP Venture Fund, a limited partnership fund that is managed by Top Technology Ventures Limited, a 100% subsidiary of IP Group plc.

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Greg Smith

15. Contact telephone number:

020 7444 0050

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFIIDRIFFIS
Date   Source Headline
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015
22nd Mar 20167:00 amRNSPositive LOXL2 results
3rd Mar 20167:00 amRNSNotice of Preliminary Results
16th Nov 20154:11 pmRNSAdoption of FRS 101 - Reduced Disclosure Framework
13th Nov 20153:08 pmRNSHolding(s) in Company
13th Nov 201511:41 amRNSHolding(s) in Company
13th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSDirectors' Share Purchase
28th Oct 20157:00 amRNSGrant of options
16th Sep 20157:00 amRNSInterim Results
21st Aug 20157:00 amRNSNotice of Interim Results
5th Aug 20157:00 amRNSSynairgen announces research collaboration
22nd Jul 20157:00 amRNSAstraZeneca commences Phase II Trial
22nd Jun 20151:41 pmRNSResult of AGM
2nd Jun 20159:37 amRNSHolding(s) in Company
15th May 201511:04 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.